Immunoliposomes and their targetsстатья
Информация о цитировании статьи получена из
Web of Science ,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 марта 2022 г.
Авторы:
Baryshnikova M.A. ,
Baryshnikov A.Yu
Журнал:
Russian Journal of General Chemistry
Том:
83
Номер:
12
Год издания:
2013
Издательство:
Maik Nauka/Interperiodica Publishing
Местоположение издательства:
Russian Federation
Первая страница:
2565
Последняя страница:
2570
DOI:
10.1134/S1070363213120554
Аннотация:
Immunoliposomes have been actively studied over the past two decades. However, researcher’s attention has still been limited to intensive preclinical trials and no one immunoliposomal formulation has passed clinical trials. This fact can be explained by a fear of complications, when mouse monoclonal antibodies are used as delivery vehicles. The situation has radically changed over the past few years. Nonimmunogenic single-chain antibodies have become an accessible research tool. Moreover, antibodies can be easily modified and conjugated with liposomes. Therefore, a vigorous breakthrough in the field of development of newgeneration immuno-liposomal formulations for oncological practice can be expected. © 2013 Pleiades Publishing, Ltd.
Добавил в систему:
Барышникова Мария Анатольевна